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Bcr-Abl, activated in chronic myelogenous leukemias, is a potent cell death inhibitor. Previous reports have
shown that Bcr-Abl prevents apoptosis through inhibition of mitochondrial cytochrome c release. We report
here that Bcr-Abl also inhibits caspase activation after the release of cytochrome c. Bcr-Abl inhibited caspase
activation by cytochrome c added to cell-free lysates and prevented apoptosis when cytochrome c was micro-
injected into intact cells. Bcr-Abl acted posttranslationally to prevent the cytochrome c-induced binding of
Apaf-1 to procaspase 9. Although Bcr-Abl prevented interaction of endogenous Apaf-1 with the recombinant
prodomain of caspase 9, it did not affect the association of endogenous caspase 9 with the isolated Apaf-1
caspase recruitment domain (CARD) or Apaf-1 lacking WD-40 repeats. These data suggest that Apaf-1
recruitment of caspase 9 is faulty in the presence of Bcr-Abl and that cytochrome c/dATP-induced exposure of
the Apaf-1 CARD is likely defective. These data provide a novel locus of Bcr-Abl antiapoptotic action and
suggest a distinct mechanism of apoptosomal inhibition.
Chronic myelogenous leukemia (CML) is a human malig-
nancy marked by the presence of a distinct cytogenetic abnor-
mality that results from a translocation between chromosomes
9 and 22, known as the Philadelphia chromosome (17). This
translocation causes aberrant expression of Bcr-Abl, a consti-
tutively active tyrosine kinase that has been directly linked to
the pathogenesis of CML. Moreover, Bcr-Abl expression is
sufficient to cause malignant transformation of hematopoietic cell
lines (15). Bcr-Abl is thought to promote malignant transforma-
tion by altering cellular adhesion properties, stimulating mito-
genic signaling pathways, and inhibiting programmed cell death
(apoptosis) (5, 17, 35). The potent ability of Bcr-Abl to inhibit cell
death limits the efficacy of apoptosis-inducing chemotherapeutics
in the treatment of CML (4). Although STI-571, a specific inhib-
itor of Bcr-Abl, has shown remarkable success in the treatment of
CML (45), the prevalence of STI-571-resistant leukemias has
been steadily increasing. This resistance arises most often from
mutations in the kinase domain of Bcr-Abl that render it insen-
sitive to STI-571 (25) or from overexpression of the Bcr-Abl
protein (31). Therefore, an understanding of the mechanisms
used by Bcr-Abl to inhibit apoptotic signaling pathways is crucial
to the development of alternative pharmacologic agents for the
chemotherapeutic treatment of CML.
In response to cellular stress such as DNA damage induced
by chemotherapeutic drugs, the cell’s mitochondria are trig-
gered to release cytochrome c (a component of the electron
transport chain) into the cytosol. Once released, cytochrome c
plays a critical role in the formation of a proteolytic cell death
machine known as the apoptosome. The formation of the ap-
optosome results in the activation of a group of zymogenic
cysteine proteases (caspases), which carry out the cell death
program (23, 38, 57). Cytosolic cytochrome c initiates apopto-
some formation by binding to the adaptor protein Apaf-1 and
promoting its oligomerization into a higher-ordered structure
(61). Oligomerization of Apaf-1 then allows binding of the
initiator caspase 9, which results in dimerization-induced self-
activation (55). Once activated, caspase 9 can cleave and acti-
vate effector caspases 3 and 7, which subsequently cleave a
number of cellular substrates. This results in orderly disman-
tling of the cell and the hallmark features of apoptosis (60).
The release of cytochrome c from the mitochondria is tightly
regulated by Bcl-2 proteins, a family comprising both proapop-
totic (e.g., Bax and Bak) and antiapoptotic (e.g., Bcl-2 and
Bcl-XL) family members (16). These proteins act as mitochon-
drial gatekeepers and regulate apoptosis by governing the re-
lease of cytochrome c. Proapoptotic members such as Bak and
Bax promote mitochondrial cytochrome c release, while the
antiapoptotic Bcl-2 and Bcl-XL proteins maintain the integrity
of the mitochondria to prevent the release of cytochrome c.
Alterations of apoptotic signaling pathways at a number of
loci allow malignant cells to evade cell death, a phenomenon
thought, in many cases, to be critical for tumor development
(24). Although regulation of caspase activation upstream of
cytochrome c release has been subject to intense scrutiny, the
regulation of apoptosis downstream of mitochondrial cyto-
chrome c release is only beginning to be understood. One
mode of caspase regulation post cytochrome c release involves
direct binding and inhibition of active caspases by the IAP
(inhibitor of apoptosis) family of proteins (20, 47). Kinase
signaling pathways have also been shown to impinge upon the
proper functioning of the apoptosome. For example, both Akt
and ERK, two kinases commonly active in cancer cells, can
phosphorylate caspase 9 and subsequently inhibit its enzymatic
activity (1, 12, 56). Furthermore, several additional proteins
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have been identified which can inhibit apoptosis by binding to
either Apaf-1 or caspase 9 (e.g., Hsp70 and Aven) to prevent
proper functioning of the apoptosome (6–8, 13, 46, 49).
Prior to cytochrome c release, Bcr-Abl can inhibit apoptosis
through regulation of Bcl-2 family members (3). Specifically,
Bcr-Abl increases expression of antiapoptotic Bcl-2 family
members such as Bcl-2 and Bcl-XL through activation of the
transcription factor STAT5 (3, 27, 48, 50). Additionally, Bcr-
Abl has also been shown to prevent mitochondrial cytochrome
c release through a posttranslational mechanism by signaling
through the phosphatidylinositol 3-kinase (PI3K)/Akt pathway
to phosphorylate and inhibit Bad (26, 36, 52). However, Bcr-
Abl has recently been reported to be a more effective inhibitor
of apoptosis than either Bcl-2 or Bcl-XL. As the Bcl-2 and
Bcl-xL proteins can potently suppress mitochondrial cyto-
chrome c release, these data suggested that Bcr-Abl might act
at additional sites, perhaps downstream of the mitochondria
(9). We report here that Bcr-Abl can act through posttransla-
tional signaling mechanisms to prevent apoptosis downstream
of mitochondrial cytochrome c release. Our data indicate that
Bcr-Abl protection from cytochrome c differs from that re-
ported for other apoptosome-inhibiting kinases (ERK and
Akt) in that caspase 9 phosphorylation does not seem to un-
derlie the protection. Rather, despite unperturbed binding to
cytochrome c, Apaf-1 from Bcr-Abl-expressing cells appears to
be defective in the ability to recruit the caspase 9 prodomain.
Collectively, these results demonstrate a novel role for Bcr-Abl
in apoptotic signaling and present a potential target for the
development of apoptosis-inducing chemotherapeutics.
MATERIALS AND METHODS
Preparation of Xenopus egg extracts. To induce egg laying, mature female frogs
were injected with 100 U of pregnant mare serum gonadotropin (Calbiochem, La
Jolla, Calif.), followed by injection (3 to 10 days later) with human chorionic
gonadotropin (Sigma, St. Louis, Mo.). Twenty to 24 h after human chorionic
gonadotropin injection, eggs were harvested for extract production. Jelly coats
were removed from the eggs by incubation with 2% cysteine (pH 8.0), after which
eggs were washed three times in modified Ringer solution (100 mM NaCl, 2 mM
KCl, 1 mM MgSO4, 2.5 mM CaCl2, 0.5 mM HEPES [pH 7.8], 0.08 mM EDTA)
and then washed in ELB (250 mM sucrose, 2.5 mM MgCl2, 50 mM KCl, 10 mM
HEPES [pH 7.7]). Eggs were packed by low-speed centrifugation at 400  g and
then supplemented with aprotinin and leupeptin (final concentration, 5 g/ml),
cytochalasin B (final concentration, 5 g/ml), and cycloheximide (50 g/ml),
after which eggs were lysed by centrifugation at 10,000  g for 15 min. The
resulting crude interphase egg extract was used to assess the spontaneous apo-
ptosis program or further fractionated into cytosolic and membrane components.
To separate mitochondrial and cytosolic components, crude interphase extract
was centrifuged for 45 min at 55,000 rpm (250,000  g) with a Beckman TLS-55
rotor (Beckman Instruments, Fullerton, Calif.). The cytosolic fraction was re-
moved and recentrifuged at 55,000 rpm for an additional 25 min, aliquoted,
frozen in liquid nitrogen, and then stored at 80°C for future use.
Cell lines and cell culture. Vector control and Bcr-Abl-expressing 32D cells (a
gift from Ann Marie Pendergast, Duke University) were maintained in RPMI
medium supplemented with 10% fetal bovine serum (FBS) and 10% WEHI
3-conditioned medium. K562 and HL60 cells were maintained in Iscove’s mod-
ified Dulbecco’s medium supplemented with 10% FBS. Human embryonic kid-
ney 293T cells and Rat-1 fibroblasts were maintained in high-glucose Dulbecco
modified Eagle medium (DMEM) supplemented with 10% FBS. For the gen-
eration of stable green fluorescent protein (GFP)-expressing or GFP- and Bcr-
Abl-expressing Rat-1 fibroblast lines, Rat-1 cells were infected with retroviruses
produced from the bicistronic retroviral vectors GFP-MIGR1 and p185 Bcr-Abl
MIGR1 (a gift from Ann Marie Pendergast) as previously described (39). Briefly,
293T cells were cotransfected with PSV2 and MIGR1 vectors with Superfect
transfection reagent (QIAGEN) in accordance with the manufacturer’s instruc-
tions. Twenty-four hours after transfection, 10 mM sodium butyrate was added
to the cell medium to enhance the virus yield. Two days posttransfection, Bcr-
Abl-containing and control GFP-containing retroviral supernatants were col-
lected. Viral supernatants were then incubated with 5.0  105 Rat-1 fibroblasts
in high-glucose DMEM supplemented with 10% FBS and 4 g of Polybrene per
ml in a volume of 10 ml for 6 h. The cells were then washed with phosphate-
buffered saline (PBS) and replenished with growth medium. Two days after
infection, cells were sorted for GFP expression. Cells were periodically resorted
to maintain 90% GFP-positive cells.
Preparation of cell extracts. Cell extracts were prepared from 32D, K562,
HL60, or Rat-1 cells containing control GFP or Bcr-Abl. Briefly, cells were
harvested, washed once with ice-cold PBS, and pelleted. Cell pellets were then
resuspended in twice the pellet volume of hypotonic lysis buffer (20 mM HEPES
[pH 7.4], 10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 1 mM
dithiothreitol [DTT], 1 mM phenylmethylsulfonyl fluoride [PMSF], 5 g of
leupeptin per ml, 5 g of aprotinin per ml, 1 mM NaVO4, 1 M okadaic acid
[Alexis Biochemicals]) and rocked at 4°C for 20 min. The cells were then lysed
by passage through a 27-gauge needle 10 times and subsequently centrifuged at
14,000 rpm (Eppendorf 5415C) for 30 min at 4°C. Alternatively, for some ex-
periments, cells were collected, washed in ice-cold PBS, pelleted, and then
resuspended in an equal volume of ice-cold cell extraction buffer [50 mM piper-
azine-N,N-bis(2-ethanesulfonic acid) (PIPES; pH 7.4), 50 mM KCl, 5 mM
EGTA, 2 mM MgCl2, 1 mM DTT, 1 mM PMSF, 5 g of leupeptin per ml, 5 g
of aprotinin per ml, 1 mM NaVO4, 1 M okadaic acid]. Cells were lysed by
freeze-thawing three times (11) and centrifuged for 30 min at 14,000 rpm (Ep-
pendorf 5415C) at 4°C. The supernatants were collected, assayed for protein
content with the Bradford assay (Bio-Rad), and either used immediately or
snap-frozen in liquid nitrogen and stored in aliquots at 80°C.
Production of purified Bcr-Abl proteins. Wild-type (WT) and kinase-dead
(K671R) p185 Bcr-Abl constructs in the MIGR1 vector were kindly provided by
Ann Marie Pendergast. The p185 inserts were cut out of the MIGR1 vector with
EcoRI and ligated into the pFastBac plasmid vector (Gibco). Recombinant
baculoviruses were produced in accordance with the Gibco Bac-to-bac protocol.
Sf9 cells were infected with Bcr-Abl (WT) or (K671R) baculovirus for 54 h, and
recombinant Bcr-Abl proteins were purified by a two-step purification strategy as
previously described (40).
Measurement of in vitro caspase activity. To activate endogenous caspases in
vitro, egg extract that had been incubated with WT or K671R Bcr-Abl (1 to 2
g/50 l of extract) or cell lysates (equivalent of 250 to 300 g of protein) were
incubated with recombinant horse heart cytochrome c (0.6 to 10 ng/l; Sigma)
and/or 1 mM dATP at 37°C for various times. For some experiments, 2 l of in
vitro-translated, [35S]methionine-labeled human procaspase 9 or catalytically
inactive human procaspase 3 (a gift from Yigong Shi, Princeton University) was
added. Protein aliquots (30 to 50 g) were removed at various times for assess-
ment of caspase processing by immunoblot analysis, sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE), and autoradiography to visu-
alize cleavage of radiolabeled caspases or measurement of DEVDase activity as
follows. Three microliters of egg extract or 5 l of mammalian cell lysate was
incubated with 10 l of the colorimetric substrate Ac-DEVD-pNA (Biomol) in
assay buffer {50 mM HEPES (pH 7.7), 100 mM NaCl, 1 mM EDTA, 10%
glycerol, 0.1% 3-[(3-cholamidopropyl)-dimethylammonio]-1-propanesulfonate
(CHAPS), 10 mM DTT } for 1 h at 37°C. The reaction was read at 405 nm with
a Labsystems Multiscan Plus plate reader (Fisher Scientific, Pittsburgh, Pa.).
Assessment of Abl immunoprecipitates. Anti-Abl antibody (BD Biosciences
Pharmingen) was used to immunoprecipitate Bcr-Abl from Bcr-Abl-expressing
Rat-1 fibroblasts. Briefly, 1 mg of cell extract was precleared with protein G
beads for 15 min at 4°C. The lysates were then incubated with 2 g of Abl
antibody and rocked at 4°C for 2 h, after which protein G beads were added, The
lysates were subsequently rocked for 1 h at 4°C, after which the beads were
washed three times in cell extraction buffer (described above). The immunopre-
cipitates were then incubated with control GFP-expressing Rat-1 cell lysates in
the presence of 20 M unlabeled ATP for 30 min at 30°C. The cell lysates were
then removed from the immunoprecipitates and assessed for cytochrome c-
induced caspase activity as described above.
Western blot analysis. Cytosolic egg extract (80 g) or Rat-1 cell lysates (100
g) were subjected to SDS-PAGE analysis, and proteins were transferred to
PVDF membranes (Immobilon P). Membranes were subsequently immunoblot-
ted with antibodies directed against phospho-ERK (Cell Signaling Technolo-
gies), rat Apaf-1 (clone 131FF; Alexis Biochemicals), and rat caspase 9 (Cell
Signaling Technologies). For some experiments, a polyclonal antibody directed
against caspase 9 (Neomarkers) was used for immunoblot analysis.
Apaf-1 and caspase 9 binding assays. The caspase 9 prodomain, Apaf-1
caspase recruitment domain (CARD), and Apaf-1 (1-543) cDNAs were gener-
ated from full-length human caspase 9 and full-length human Apaf-1 (gift from
Xiaodong Wang, University of Texas Southwestern) and subsequently cloned
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into the pGEX-KG expression plasmid. Recombinant GST fusion proteins were
produced in BL21 bacteria by inducing protein expression with 0.2 mM isopro-
pyl--D-thiogalactopyranoside (IPTG) at 18°C overnight. GST fusion proteins
were purified with glutathione beads by a standard protocol (21). To assess the
ability of Apaf-1 and caspase 9 to bind to cytochrome c, cell lysates from Rat-1
control GFP- or Bcr-Abl-expressing cells (500 g of total protein in a 100-l total
volume) were incubated with cytochrome c-Sepharose (Sigma) in the presence of
1 mM dATP for 30 min at room temperature and then incubated for an addi-
tional 60 min at 4°C. The cytochrome c-Sepharose was subsequently washed
three times with cell extraction buffer containing 300 mM NaCl, and bound
proteins were then assessed via SDS-PAGE and Western blot analysis. To assess
the ability of Apaf-1 or caspase 9 to bind to the Apaf-1 CARD, Apaf-1 (1-543),
or the caspase 9 prodomain, the GST fusion proteins were incubated with cell
lysates from control GFP- or Bcr-Abl-expressing Rat-1 cells in the presence of 1
mM dATP for 30 min at room temperature. The GST fusion proteins were then
recaptured on glutathione beads. The bead-bound protein complexes were
washed three times with cell extraction buffer containing 300 mM NaCl and then
subjected to SDS-PAGE and immunoblot analysis.
In vivo labeling of Rat-1 fibroblasts. control GFP- and Bcr-Abl-expressing
Rat-1 fibroblasts were plated at a density of 5.0  105 per 100-mm-diameter dish.
Twenty-four hours later, the growth medium was replaced with phosphate-free,
high-glucose DMEM supplemented with 10% dialyzed FBS and the cells were
returned to the incubator for 2 h. Five millicuries of 32Pi was then added, and the
cells were incubated for an additional 5 h. The cells were then washed three times
with warm, phosphate-free DMEM and subsequently lysed in 1 ml of radioimmu-
noprecipitation assay buffer (50 mM Tris-HCl [pH 7.4]; 1% NP-40; 0.25% Na
deoxycholate; 150 mM NaCl; 1 mM EDTA; 1 mM PMSF; 1 g each of aprotinin,
leupeptin, and pepstatin per ml; 1 mM Na3VO4; 1 mM NaF) containing 30 mM Na
pyrophosphate. The cell lysates were then incubated on ice for 15 min and then
centrifuged at 14,000 rpm (Eppendorf 5415C) for 20 min at 4°C. Total protein was
assessed with the Bradford assay (Bio-Rad). Because there are no antibodies avail-
able that immunoprecipitate rat caspase 9, endogenous rat caspase 9 was captured
from the radiolabeled cell lysates with the GST fusion protein containing the CARD
of Apaf-1, as described above. The bound proteins were then subjected to SDS-
PAGE and autoradiography. In parallel, unlabeled control GFP- and Bcr-Abl-
expressing Rat-1 cells were subjected to the same cell lysis protocol and immunoblot
analysis was performed with the rat-specific caspase 9 antibody described above.
Kinase assays and phosphotyrosine assessment. Human procaspase 9 was
immunoprecipitated from human embryonic kidney 293T cells with polyclonal
caspase 9 antiserum (2 g of antibody per mg of total protein; BD Biosciences
Pharmingen). The caspase 9 or immunoglobulin G control precipitates were then
used as substrates in an in vitro kinase assay with control GFP- or Bcr-Abl-
expressing Rat-1 cell lysates. Briefly, 500 g of control GFP- or Bcr-Abl-express-
ing Rat-1 cell lysate (5 mg/ml) was supplemented with 20 M unlabeled ATP, 15
mM MgCl2, and 1 Ci of [	-32P]ATP and then incubated for 30 min at 30°C. The
precipitates were washed three times with cell extraction buffer (described
above) containing 300 mM NaCl and then subjected to SDS-PAGE and auto-
radiography. Recombinant ERK (Upstate Biotechnology) was incubated in
GFP-expressing control cell lysate to serve as a positive control for caspase 9
phosphorylation (1). The Apaf-1 (1-543)–GST fusion protein also served as a
substrate for in vitro kinase assays with control GFP- and Bcr-Abl-expressing
Rat-1 cell lysates. For these experiments, GST–Apaf-1 (1-543), GST-Crk, or
GST alone bound to glutathione beads was incubated in control GFP- or Bcr-
Abl-expressing Rat-1 lysate (5 mg/ml) supplemented with 20 M unlabeled ATP,
15 mM MgCl2, and 1 Ci of [	-32P]ATP for 30 min at 30°C. The beads were then
washed three times with cell extraction buffer containing 300 mM NaCl and
subjected to SDS-PAGE and autoradiography. To assess whether Bcr-Abl phos-
phorylates Apaf-1 directly, endogenous Apaf-1 was immunoprecipitated from
control GFP- or Rat-1-expressing cell lysates with a rat-specific Apaf-1 antibody
(clone 131FF; Alexxa). Briefly, 1 g of Apaf-1 antibody was precoupled to 30 l
of protein G-Sepharose (Sigma) in PBS for 1 h by rocking at 4°C. Control GFP-
or Bcr-Abl-expressing cell lysates (1 mg) were then incubated with the bead-
bound antibody for 2 h at 4°C. The immunoprecipitates were subsequently
washed five times with cell extraction buffer containing 300 mM NaCl and then
immunoblotted with phosphotyrosine (Upstate Biotechnologies) and rat Apaf-1
antibodies (clone 131FF; Alexis Biochemicals).
Microinjection studies. Rat-1 fibroblasts were microinjected with soluble cy-
tochrome c as previously described (42). The concentration of bovine heart
cytochrome c (Sigma) injected was 1 g/l. In order to mark the microinjected
cells, the microinjection solution (100 mM KCl, 10 mM KPi [pH 7.4]) contained
4 mg of rhodamine dextran per ml. Cell viability was determined by counting the
rhodamine-positive cells that had intact, phase-bright cell bodies immediately
after injection and at various times postinjection. Cell survival is expressed as a
percentage of the original number of cells microinjected.
RESULTS
Bcr-Abl kinase activity prevents cytochrome c-induced
caspase activity in cytosolic Xenopus egg extracts. Extracts pre-
pared from Xenopus eggs have proven to be a powerful tool for
the faithful in vitro reconstitution of many of the biochemical
events of apoptosis (37). When egg extracts are incubated at
room temperature for an extended period of time, mitochon-
drial cytochrome c is released, leading to caspase activation,
cleavage of cellular substrates, and nuclear fragmentation. As
the egg extracts used for apoptosis assays are transcriptionally
and translationally inactive, we used this system to determine if
Bcr-Abl-mediated inhibition of apoptosis could occur through
an entirely posttranslational mechanism, independently of al-
tered gene expression. For this purpose, crude egg extract was
incubated with WT Bcr-Abl, enzymatically inactive (K671R)
Bcr-Abl, or buffer alone and caspase 3 activity was monitored
over time with a synthetic peptide substrate (DEVD-pNA).
Interestingly, we found that treatment of extracts with WT
recombinant Bcr-Abl completely inhibited the spontaneous
apoptotic program in the egg extract (Fig. 1A). We did observe
a slight delay in apoptosis with the K671R Bcr-Abl protein,
suggesting that some kinase-independent actions of Bcr-Abl
may contribute to its potent antiapoptotic effects.
As the egg apoptotic program is entirely dependent upon
mitochondrial cytochrome c release, a process previously re-
ported to be inhibited by Bcr-Abl, these results were perhaps
not surprising. However, when we prepared isolated egg cy-
tosol devoid of mitochondria, we found that WT Bcr-Abl, but
not its inactive counterpart, could also prevent the robust
caspase activation resulting from addition of purified exoge-
nous cytochrome c (which, as in mammalian cells, nucleates
apoptosome formation (30, 56) (Fig. 1B). Moreover, treatment
of extracts with WT but not kinase-inactive Bcr-Abl was able to
prevent the cleavage of in vitro-translated, 35S-labeled pro-
caspase 9, as well as the development of caspase 9 activity as
measured by LEHDase activity (Fig. 1C and D). Although
cleavage is not required for caspase 9 activity, its cleavage can
serve as an indicator that it has been activated. Thus, taken
together, our results strongly suggest that Bcr-Abl can inhibit
cytochrome c-induced apoptosome activation in the absence of
de novo transcription or translation. Moreover, although
K671R Bcr-Abl had a minor inhibitory effect on the sponta-
neous apoptotic program in crude egg extracts (containing
mitochondria; Fig. 1A), this protein was unable to prevent
cytochrome c-induced apoptosome activation, suggesting that
any kinase-independent effects of Bcr-Abl are probably ex-
erted upstream of the mitochondria and that the post-cyto-
chrome c effects of Bcr-Abl are kinase dependent.
Bcr-Abl expression prevents cytochrome c-induced caspase
activity in cell extracts. Given that Bcr-Abl was able to inhibit
apoptosome activity and caspase activation in Xenopus egg
extracts, we wished to extend these results to mammalian cells.
In mammalian cell extracts, addition of dATP and/or cyto-
chrome c has been shown to initiate formation of the apopto-
some, caspase activation, and caspase-mediated cleavage of
substrates (presumably, dATP allows apoptosome formation
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nucleated by cytochrome c that has leaked into the cytosol
during extract preparation) (34). Hence, we assessed cyto-
chrome c-induced caspase activity in lysates prepared from the
human acute myelocytic leukemia cell line HL60, which does
not express Bcr-Abl, and the K562 cell line, which is derived
from a patient with CML and thus has abundant levels of
Bcr-Abl protein. Addition of cytochrome c and dATP to HL60
cell lysates provoked marked caspase 3 activity, while lysates
from the K562 cells were notably resistant to cytochrome c,
failing to exhibit substantial levels of cytochrome c-induced
caspase 3 activity (Fig. 2A). These data suggested that Bcr-Abl
could exert its effects downstream of cytochrome c release in
human CML cells. However, these cell lines do not provide an
ideal system for studying post-cytochrome c protection from
apoptosis in that they are not isogenic and thus do not allow
assessment of Bcr-Abl-specific effects. Therefore, we obtained
mouse 32D lymphoblasts stably expressing either GFP alone or
GFP and Bcr-Abl from a bicistronic construct. We also gener-
ated Rat-1 fibroblasts stably expressing either GFP alone or
both GFP and Bcr-Abl. Cell lysates prepared from these cells
were then tested for the ability to develop caspase activity upon
addition of cytochrome c and dATP. Consistent with the re-
sults obtained with K562 cells, we found that there was a
marked inhibition of cytochrome c-induced caspase activation
in extracts prepared from either mouse or rat cells expressing
Bcr-Abl (Fig. 2B, C, and D). These data corroborated our
FIG. 1. Post-cytochrome c protection by Bcr-Abl in Xenopus egg extracts. (A) Crude egg extract was incubated with buffer alone, WT Bcr-Abl,
or kinase-dead (K671R) Bcr-Abl, and caspase 3 activity was measured at various time points. Caspase 3 activity was measured spectrophoto-
metrically via cleavage of the colorimetric caspase substrate DEVD-pNA. (B) Cytosolic egg extract was pretreated for 30 min with WT Bcr-Abl,
K671R Bcr-Abl, or buffer alone and then incubated with 0.6 ng of cytochrome c per l. Caspase 3 activity was measured by cleavage of DEVD-pNA
over time. (C) Cytosolic egg extract was pretreated for 30 min with WT or K671R mutant Bcr-Abl and then incubated with 0.7 ng of cytochrome
c per l for various times. Caspase 9 activity was measured spectrophotometrically by cleavage of the colorimetric caspase 9 substrate LEHD-pNA.
(D) In vitro-translated, 35S-labeled procaspase 9 and soluble cytochrome c (0.6 ng/l) were added to cytosolic egg extracts that were pretreated
with WT or K671R mutant Bcr-Abl. Cleavage of procaspase 9 was assessed via autoradiography. In panels A to C, the graphs are representative
of at least three independent experiments. OD405, absorbance reading at 405 nm.
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observations on Xenopus egg extracts demonstrating that Bcr-
Abl can protect from cytochrome c-induced caspase activation.
The failure of cytochrome c to elicit DEVDase activity in the
Bcr-Abl-expressing cell lysates implied that the effector
caspase, caspase 3, could not be activated by cleavage in the
presence of active Bcr-Abl. To address this issue, we supple-
mented the cell-free Rat-1 lysates with in vitro-translated, 35S-
radiolabeled, catalytically inactive caspase 3 and then activated
the lysates with cytochrome c and dATP. As shown in Fig. 3A,
processing of radiolabeled, catalytically inactive caspase 3
(which yields only the caspase 9-induced cleavage product) was
greatly dampened in lysates containing Bcr-Abl compared with
that in lysates expressing GFP alone. Furthermore, we found
that cleavage of endogenous rat caspase 9 was also largely
inhibited in these lysates following cytochrome c addition (Fig.
3B). Note that all of the extracts tested were supplemented
with dATP, most likely accounting for some processing in the
absence of exogenous cytochrome c. Taken together, these
results are very similar to those shown in Fig. 1 for Bcr-Abl-
treated egg extracts, although the inhibition of caspase pro-
cessing was not as complete, most likely owing to the lower
level of Bcr-Abl expression in the Rat-1 cells. Although, as
mentioned above, caspase 9 processing is not required for its
enzymatic activity, the inhibition of cleavage did imply a damp-
ening of both caspase 3 and caspase 9 activities in these ex-
tracts as both contribute to the cleavage of caspase 9. There-
fore, these data pointed to some component of the
apoptosome as the target of Bcr-Abl action.
Posttranslational inhibition of apoptosome function by Bcr-
Abl in mammalian cell lysates. Bcr-Abl is known to regulate
the transcription of multiple genes and to activate a number of
signaling pathways (e.g., mitogen-activated protein kinase and
PI3 kinase pathways) (14, 41, 52, 53). Because the cell extract
experiments described above had been carried out with lysates
FIG. 2. Post-cytochrome c protection by Bcr-Abl in mammalian cell lysates. Cell lysates were prepared from human (A), mouse (B), or rat
(C) cells as described in Materials and Methods. The lysates were incubated with 5 ng of cytochrome c per l and 1 mM dATP, and caspase 3
activity was then assayed by measuring the cleavage of DEVD-pNA over time. (D) DEVDase activity was measured in the control GFP (C)- and
Bcr-Abl (B)-expressing Rat-1 lysates following the addition of 1 mM dATP and various doses of soluble cytochrome c. The results shown for panels
A to D are representative of at least three independent experiments. OD405, absorbance reading at 405 nm.
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prepared from cells stably expressing Bcr-Abl, it was possible
that proteins up (or down)-regulated by Bcr-Abl in the intact
cells were instrumental in promoting protection from apopto-
sis. To rule out this possibility, we introduced Abl immunopre-
cipitates from cells expressing GFP alone or Bcr-Abl into naive
cell lysates prepared from Rat-1 cells. Lysates treated with Abl
precipitates from Bcr-Abl-expressing cells, but not precipitates
from control cells, were also protected from the action of
cytochrome c. This suggested that Bcr-Abl-mediated modifi-
cation of a cytosolic factor renders the lysate refractory to
cytochrome c (Fig. 4A). These results confirm our Xenopus
data presented above, demonstrating that Bcr-Abl can protect
from cytochrome c-induced apoptosis without inducing
changes in transcription-translation.
In some systems, regulation of apoptosis after the release of
cytochrome c has been reported to be regulated by changes in
the protein levels of the core apoptosomal proteins Apaf-1 and
caspase 9 (29). Indeed, in some leukemic cell lines, Apaf-1 is
underexpressed, potentially accounting for the observed pro-
tection from cytochrome c-induced caspase activation. To ad-
dress this issue, we examined Apaf-1 and caspase 9 levels in
both control GFP- and Bcr-Abl-expressing rat fibroblasts,
which had been markedly different in their responsiveness to
cytochrome c. We found that the expression of the Apaf-1 and
caspase 9 proteins was equivalent in these cells (Fig. 4B),
strongly suggesting that Bcr-Abl could confer protection from
cytochrome c without altering the concentration of the core
apoptosomal components.
Bcr-Abl has been reported to activate ERK and Akt in some
cell types, and both of these kinases have been shown to phos-
phorylate and inactivate caspase 9. However, we found no
increase in ERK activation (as measured by immunoblotting
against phospho-ERK) by Bcr-Abl in cytosolic egg extracts,
where cytochrome c-induced caspase activity was inhibited,
FIG. 3. Bcr-Abl prevents processing of caspase 3 and caspase 9.
(A) In vitro-translated, 35S-radiolabeled, catalytically inactive pro-
caspase 3 was added to control GFP- or Bcr-Abl-expressing Rat-1
lysates in the presence of soluble cytochrome c (1 ng/l). The process-
ing of caspase 3 was observed via autoradiography. (B) Cell lysates
from control GFP- or Bcr-Abl-expressing Rat-1 fibroblasts were incu-
bated with 1 mM dATP and various concentrations of soluble cyto-
chrome c. The processing of endogenous caspase 9 was assayed by
Western analysis. Note that the fragment derived from caspase 9-me-
diated caspase 9 cleavage (the middle of the three cleaved bands
indicative that the apoptosome has been activated) is barely visible in
the presence of Bcr-Abl. The small amount of (unsuppressed) residual
caspase 9 activity in this experiment most likely led to caspase 3
activation, resulting in amplification of caspase 9 processing through
caspase 3-mediated caspase 9 cleavage (the upper band of the triplet). FIG. 4. Bcr-Abl post-cytochrome c protection in cell lysates occurs bya posttranslational mechanism. (A) Control GFP-expressing cell lysates
were preincubated with Abl immunoprecipitates from control GFP- or
Bcr-Abl-expressing Rat-1 cells, after which caspase activity was assessed
following the addition of 1 ng of soluble cytochrome c per l. Caspase 3
activity was measured by assessing the cleavage of the colorimetric
DEVD-pNA substrate. The results shown are representative of three
independent experiments. (B) Control GFP (lane C)- and Bcr-Abl (lane
B)-expressing Rat-1 lysates were immunoblotted for the Apaf-1 and
caspase 9 proteins. (C) Cytosolic Xenopus egg extracts were pretreated
with Mos, WT Bcr-Abl (WT), or kinase-dead Bcr-Abl (K671R). ERK
activation was assessed by Western immunoblot analysis with an antibody
directed against phospho-ERK. OD405, absorbance reading at 405 nm.
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although activated ERK was readily detected in extracts
treated with the mitogen-activated protein kinase kinase
kinase Mos (Fig. 4C). As these extracts were devoid of mem-
brane components, a requirement for PI3K-mediated Akt ac-
tivation, it seems unlikely that Akt could mediate the post-
cytochrome c protection by Bcr-Abl in the egg extract.
Moreover, a strong inhibition of cytochrome c-induced caspase
activity was observed in rat and mouse cells expressing Bcr-
Abl, and caspase 9 from these species does not contain an Akt
phosphorylation site (44). Furthermore, in the Rat-1 cells used
in our cytochrome c protection experiments, Bcr-Abl expres-
sion did not enhance the activation of either ERK or Akt as
assessed by the presence of phospho-ERK and phospho-Akt
levels in Rat-1 cells (Z. T. Schafer, P. B. Deming, and S.
Kornbluth, unpublished data). Finally, we looked to see if
caspase 9 could be phosphorylated in lysates from Bcr-Abl-
expressing cells. As shown in Fig. 5A, immunoprecipitated
human procaspase 9 (containing the reported Akt phosphor-
ylation site) was not radiolabeled after incubation in lysates
with [	-32P]ATP, either in the presence or in the absence of
Bcr-Abl under conditions that allowed both autophosphoryla-
tion of Bcr-Abl and ERK-mediated phosphorylation of
caspase 9. Moreover, there was no detectable phosphorylation
of caspase 9 precipitated from Bcr-Abl-expressing Rat-1 cells
metabolically labeled with orthophosphate (Fig. 5B). Taken
together, these data suggest that ERK and Akt are unlikely to
play a role in Bcr-Abl-mediated inhibition of apoptosis post
cytochrome c release.
Bcr-Abl inhibits cytochrome c-induced apoptosis in intact
cells. Although our accumulated data obtained with cell lysates
indicated that Bcr-Abl could inhibit proper apoptosomal func-
tion in vitro, we wished to validate these findings by demon-
strating that cytochrome c introduced directly into the milieu
of an intact Bcr-Abl-positive cell cytoplasm would be effec-
tively prevented from activating caspases. Fibroblast cell lines
have been demonstrated to undergo rapid, caspase-dependent
cell death following cytosolic microinjection of cytochrome c
(10, 32), thus circumventing the mitochondria in an intact
cellular setting. Thus, we microinjected Rat-1 fibroblasts ex-
pressing either GFP alone or Bcr-Abl with cytochrome c and
examined these cells for apoptotic death. Cells expressing only
GFP died rapidly after microinjection with 1 g of cytochrome
c per l, while cells expressing Bcr-Abl were highly resistant to
apoptosis (Fig. 6A and B). The effect was readily evident as
microinjected cells expressing GFP alone began to bleb, round
up, and lift off the plate while microinjected cells expressing
Bcr-Abl remained intact and adherent. Indeed, within 1 h of
microinjection, greater than 80% of injected control cells had
died while less than 20% of the Bcr-Abl-expressing cells had
done so. These data confirm our in vitro findings demonstrat-
ing that Bcr-Abl expression renders cells refractory to the
apoptosis-inducing activity of cytoplasmic cytochrome c.
Bcr-Abl inhibits the interaction of caspase 9 with Apaf-1. As
our results (obtained with both lysates and intact cells) sug-
gested a likely role for Bcr-Abl in regulating the apoptosome,
we sought to determine if interactions between apoptosomal
components occur normally in cells expressing Bcr-Abl. To
address this question, we took advantage of the ability of the
isolated prodomain of caspase 9, which contains the Apaf-1
binding determinants (the CARD), to retrieve fully nucleated
apoptosomes from crude cell lysates (58). The soluble GST-
tagged caspase 9 prodomain was added to lysates from control
GFP- or Bcr-Abl-expressing cells, and apoptosomes were then
precipitated with glutathione-Sepharose. These precipitates
were resolved by SDS-PAGE and immunoblotted with anti-
Apaf-1 antibody. It is important to note that the binding of
Apaf-1 to the caspase 9 prodomain should occur only after
Apaf-1 “activation” by the addition of dATP. Accordingly, in
control cell lysates from GFP-expressing cells, Apaf-1 was
bound to the caspase 9 prodomain only in samples supple-
mented with dATP (Fig. 7A). However, the ability of Apaf-1 to
bind to the caspase 9 prodomain in activated lysates was se-
verely compromised in the presence of Bcr-Abl (Fig. 7A).
These data suggested that recruitment of the caspase 9 prodo-
main by Apaf-1 might be faulty in the presence of Bcr-Abl.
One simple explanation for the above data is that the
caspase 9 prodomain was modified in some way or bound to an
inhibitory factor, thus blocking recruitment to the Apaf-1 CARD.
If this were the case, endogenous caspase 9 would be expected to
be defective in recruitment to the isolated Apaf-1 CARD. To test
FIG. 5. Bcr-Abl signaling does not induce phosphorylation of
caspase 9. (A) Endogenous caspase 9 (cas-9) was immunoprecipitated
from 293T cells, and in vitro kinase assays were performed with control
GFP (lanes C)- or Bcr-Abl (lanes B)-expressing cell lysates supple-
mented with [	-32P]ATP under conditions in which Bcr-Abl was au-
tophosphorylated (bottom). Lysates were treated with recombinant
active ERK (lanes E) as a control for caspase 9 phosphorylation. IgG,
immunoglobulin G. (B) control GFP (lane C)- and Bcr-Abl (lane
B)-expressing Rat-1 fibroblasts were radiolabeled with orthophos-
phate. Endogenous caspase 9 was captured with a GST fusion protein
containing the CARD of Apaf-1. Caspase 9 bound to the Apaf-1
CARD was then subjected to SDS-PAGE and autoradiography or
immunoblot analysis with an antibody directed against rat caspase 9.
The values on the left are molecular size markers in kilodaltons.
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this, we generated the isolated CARD derived from Apaf-1 as a
GST fusion protein and examined the ability of this recombinant
protein to bind caspase 9 from cell lysates. Under normal circum-
stances, dATP would drive the oligomerization of full-length
Apaf-1 in a fashion that exposes the CARD, making it available
to bind caspase 9. By using the CARD alone, we circumvented
this step, enabling us to observe recruitment of caspase 9 in the
absence of dATP. Surprisingly, we found that endogenous
caspase 9 bound to the exposed Apaf-1 CARD equivalently in
lysates from control GFP- and Bcr-Abl-expressing cells (Fig. 7B).
This suggests that there is no inherent defect in caspase 9 derived
from Bcr-Abl-containing cell lysates that would prevent its re-
cruitment to Apaf-1. These findings are consistent with the data
presented above that demonstrate no detectable phosphorylation
of caspase 9 in the presence of Bcr-Abl. However, these data raise
the possibility that Apaf-1 function was altered in some manner
(e.g., phosphorylation) that precluded its effective recruitment of
caspase 9. In fact, the Apaf-1 (1-543) protein was well phosphor-
ylated in the presence of Bcr-Abl (Fig. 7C). This phosphorylation
did not appear to be mediated directly by Bcr-Abl as there was no
evidence of tyrosine phosphorylation when full-length Apaf-1 was
immunoprecipitated from Bcr-Abl-expressing Rat-1 cells (Fig.
7D) or when Apaf-1 (1-543) was incubated in the presence of
Bcr-Abl (P. B. Deming, Z. T. Schafer, and S. Kornbluth, unpub-
lished data). While Apaf-1 is not known to be regulated by phos-
phorylation, these data raise the intriguing possibility that post-
cytochrome c protection from apoptosis by Bcr-Abl involves
inhibitory phosphorylation of Apaf-1.
One potential explanation for apoptosome inhibition in the
presence of Bcr-Abl might be a compromised ability of Apaf-1
to interact with cytochrome c. To address this possibility, we
examined the binding of endogenous Apaf-1 to cytochrome c
immobilized on Sepharose. As shown in Fig. 7E, binding of
Apaf-1 by this resin was equivalent in the presence and ab-
sence of Bcr-Abl. Therefore, it appeared unlikely that Bcr-Abl-
exposed Apaf-1 had a markedly lowered affinity for cyto-
chrome c. However, taking advantage of the fact that
immobilized cytochrome c could very efficiently bind Apaf-1
from the lysates, we looked to see if these beads could, in
effect, nucleate Apaf-1/caspase 9 complex-containing apopto-
somes. We suspected that this might be the case as the immo-
bilized cytochrome c beads had been found to activate caspases
effectively in Xenopus egg extracts and mammalian cell lysates
(J. S. Tashker, P. B. Deming, and S. Kornbluth, unpublished
data). In performing these binding experiments with lysates
from control GFP- and Bcr-Abl-expressing cells, we found that
Apaf-1/cytochrome c complexes were markedly defective in
the ability to recruit caspase 9 in the presence of Bcr-Abl (Fig.
7F). These data are fully consistent with our previously men-
tioned results and suggest that Apaf-1, rather than caspase 9,
might be targeted by Bcr-Abl to prevent caspase 9 binding.
Interestingly, this defect was eliminated by removal of the
C-terminal WD-40 repeats of Apaf-1 (Fig. 7G). Specifically,
Apaf-1 lacking the WD-40 repeats [Apaf-1 (1-543)] was, like
the isolated CARD, able to recruit caspase 9 equally well in the
presence and absence of Bcr-Abl. Given these results, it is
attractive to speculate that cytochrome c-induced exposure of
the CARD is defective in Bcr-Abl-expressing cells (possibly
because of the phosphorylation of Apaf-1), rendering full-
length, but not truncated, Apaf-1 unable to recruit caspase 9.
DISCUSSION
The development of leukemias may result not only from
inappropriate cell proliferation but also from a failure of cells
to undergo timely cell death. In addition, strong inhibition of
apoptotic cell death is widely believed to underlie the resis-
tance of leukemic cells to conventional chemotherapeutics
(35). Although the clinical use of the kinase inhibitor STI-571
has been of remarkable utility in the treatment of CML, the
emergence of STI-571-resistant Bcr-Abl mutants makes the
search for alternative chemotherapeutics imperative (22). It is
well documented that Bcr-Abl can very potently inhibit apo-
ptotic induction by conventional chemotherapeutics (51). This
resistance has been attributed to a block in the promotion of
mitochondrial cytochrome c release, through both transcriptional
and posttranslational regulation of Bcl-2 family members (3, 26,
FIG. 6. Bcr-Abl prevents apoptosis induced by microinjection of
cytochrome c. (A) Rat-1 fibroblasts expressing either a GFP control or
Bcr-Abl were microinjected with 1 g of cytochrome c (Cytc) per l
and with rhodamine dextran (Rhod Dex; to visualize injected cells).
Representative pictures are shown in panel B.
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27, 36, 48, 50, 52). We report here that Bcr-Abl also has the ability
to robustly inhibit the apoptotic signaling cascade downstream of
the mitochondria, at the level of the apoptosome. This novel
function for Bcr-Abl occurs through a posttranslational mecha-
nism that inhibits the cytochrome c-triggered recruitment of
caspase 9 by Apaf-1. These data reveal a novel effect of Bcr-Abl
that could potentially be exploited to increase the efficacy of
CML-directed chemotherapies.
Post-cytochrome c protection from apoptosis. The existence
of cellular mechanisms to prevent caspase activation by cytoplas-
mic cytochrome c has only recently been appreciated. In several
instances, resistance to cytochrome c has been shown to reflect a
direct down-regulation of apoptosomal components. For exam-
ple, a strong correlation between chemoresistance and decreased
Apaf-1 protein levels has been reported for some leukemic cells,
as well as bladder and skin cancers (28, 29, 33, 54). Moreover,
downregulation of caspase 3 protein has been correlated with
inhibition of cell death in some breast cancer cell lines and tissues
(19). In addition to pathological blocks to cytochrome c-induced
caspase activation, neuronal cells with limited proliferative capac-
ity have also been shown to exhibit resistance to apoptosis follow-
ing mitochondrial cytochrome c release (18). Interestingly, this
feature of neuronal development can be recapitulated in PC-12
cells as they differentiate into neurons (59).
Experiments reported here, as well as in other published
reports, suggest that posttranslational mechanisms to abort
apoptosome function can also contribute significantly to cyto-
chrome c resistance (or, more generally, chemoresistance).
Although some leukemic cells reportedly have less Apaf-1 than
their normal counterparts do, we did not observe this in our
cells expressing Bcr-Abl. Rather, simple addition of Bcr-Abl to
either mammalian or Xenopus cytoplasm was sufficient to con-
fer cytochrome c resistance, highlighting the existence of
purely posttranslational mechanisms of apoptosomal inhibi-
tion. In this regard, it is interesting that ovarian cancer cells
have also been reported to have an improperly formed apo-
ptosome, (33), although the mechanism for this is not known.
Inhibition of the apoptosome by Bcr-Abl. With regard to
posttranslational mechanisms for inhibiting the apoptosome,
both Akt and activated ERK kinases have been reported to act
through phosphorylation of caspase 9 (1, 12, 56). Despite re-
ports that Bcr-Abl can activate Akt and ERK, we note that
Bcr-Abl was clearly able to protect from apoptosis in the ab-
FIG. 7. Bcr-Abl inhibits caspase 9 recruitment to the apoptosome. GST fusion proteins containing the prodomain of caspase 9 (A), the CARD
of Apaf-1 (B), or Apaf-1 (1-543) (G) were incubated with control GFP (lanes C)- or Bcr-Abl (lanes B)-expressing lysates in the presence of 1 mM
dATP. GST proteins were then rebound to glutathione beads (GSH), and the binding ability of Apaf-1 (A) or caspase 9 (B and G) was examined
via immunoblot analysis. (C) GST–Apaf-1 (1-543), GST, or GST-Crk protein was incubated with [	-32P]ATP in either control GFP (lane C)- or
Bcr-Abl (lane B)-expressing cell lysates, and radiolabeling was assessed via autoradiography. (D) Apaf-1 was immunoprecipitated from either
control GFP (lane C)- or Bcr-Abl (lane B)-expressing lysates, and precipitates were immunoblotted (IB) for Apaf-1 or phosphotyrosine (P-Tyr).
Anti-Abl immunoprecipitates (IP) were also immunoblotted for P-Tyr as a positive control for the phosphotyrosine Western analysis. (E and F)
Control GFP (lane C)- or Bcr-Abl (lane B)-expressing lysates were incubated with cytochrome c-Sepharose and 1 mM dATP. The binding ability
of Apaf-1 (E) and caspase 9 (F) was then examined by immunoblot analysis.
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sence of any detectable ERK activation. Furthermore, the re-
ported Akt phosphorylation site on human caspase 9 is not
conserved in rodents (i.e., Rat-1 cells) and recombinant human
caspase 9 mutated at the reported Akt site failed to override
the Bcr-Abl-induced protection from cytochrome c in Xenopus
egg extracts (J. S. Tashker and S. Kornbluth, unpublished).
Finally, it is also of interest that previously published data have
indicated that activation of PI3K (which leads to activation of
Akt) does not detectably contribute to the antiapoptotic action
of Bcr-Abl (2). For neither Akt nor ERK has it been deter-
mined whether caspase 9 phosphorylation results in a defect in
proper apoptosomal assembly rather than direct inhibition of
caspase 9 enzymatic activity.
Phosphorylation of caspase 9 is unlikely to be relevant to this
Bcr-Abl-mediated action in that we were unable to detect in
vitro phosphorylation of caspase 9 in lysates from Bcr-Abl-
expressing cells or in vivo phosphorylation of caspase 9 cap-
tured from orthophosphate-labeled Bcr-Abl-expressing cells.
Our data indicate that Bcr-Abl kinase activity inhibited the
activation of caspases 3 and 9 by interfering with the binding of
the prodomain of caspase 9 to the Apaf-1 CARD. Such a
failure of recruitment would be expected to prevent dimeriza-
tion-induced activation. Because the isolated CARD of Apaf-1
was unperturbed in its ability to recruit endogenous caspase 9
from Bcr-Abl cell lysates, it seems quite unlikely that the
caspase 9 from those cells is intrinsically unable to incorporate
itself into the apoptosome. Rather, these data suggested that
Apaf-1 might be the target of inhibition. In support of this
hypothesis, the isolated prodomain of caspase 9 could not
efficiently retrieve endogenous Apaf-1 from the Bcr-Abl ly-
sates. Again, were modification of the caspase 9 prodomain (or
binding of an inhibitory factor) responsible for the apoptoso-
mal defect, it seems likely that the prodomain of endogenous
caspase 9 would have been subject to the same regulation,
precluding its recruitment to the Apaf-1 CARD resin.
In that the Apaf-1 (1-543) fragment recruited endogenous
caspase 9 equally well from control GFP- and Bcr-Abl-express-
ing cells, but endogenous cytochrome c-bound Apaf-1 re-
cruited endogenous caspase 9 differentially in these cells, it
seems reasonable to speculate that cytochrome c/dATP-in-
duced exposure of the Apaf-1 CARD was impaired by Bcr-Abl
signaling. Although Apaf-1 does not appear to be tyrosine
phosphorylated (Fig. 7D) and thus is not likely to be a direct
Bcr-Abl substrate, we have shown increased total phosphory-
lation of the Apaf-1 (1-543) fragment in the presence of Bcr-
Abl (Fig. 7C). Therefore, it is plausible that phosphorylation of
Apaf-1 serves either to prevent the requisite cytochrome c-
dATP-induced conformational change of Apaf-1 to expose the
CARD or that phosphorylated residues serve as docking sites
for factors that might occlude subsequent binding of pro-
caspase 9. Although definitive proof of this hypothesis will
await identification of de novo phosphorylation sites on endog-
enous Apaf-1, our data largely preclude other known mecha-
nisms of apoptosomal inhibition. Indeed, we have assayed the
reported apoptosomal inhibitors Aven, Hsp70, and XIAP for
differential binding to Apaf-1 and/or caspase 9 in the presence
and absence of Bcr-Abl and have observed no significant differ-
ences (Z. T. Schafer, P. B. Deming, and S. Kornbluth, unpub-
lished data). Moreover, although Bcr-Abl has been demonstrated
to inhibit paclitaxel-induced apoptosis through transcriptional up-
regulation of Hsp70 (43), we found no change in Hsp70 expres-
sion levels due to the expression of Bcr-Abl in Rat-1 fibroblasts
(Z. T. Schafer and S. Kornbluth, unpublished data).
Taken together, our data derived from the use of Xenopus
egg extracts, mammalian cell lysates, and the cytosolic micro-
injection of cytochrome c demonstrate that a posttranslational
mechanism inhibits apoptosis downstream of cytochrome c
release both in vitro and in intact cells. These findings are
consistent with a recent report that Bcr-Abl is a more potent
inhibitor of apoptosis than Bcl-XL, as would be expected if
Bcr-Abl had additional loci of action, acting not only to pre-
vent cytochrome c release but also to prevent downstream
effects of cytochrome c (9). Although prevention of cyto-
chrome c release might be sufficient to inhibit apoptosis under
some circumstances, such protective mechanisms are not ab-
solute. Indeed, it is likely that large amounts of cellular dam-
age, as might be incurred following treatment with chemother-
apeutics, could lead to some transit of cytochrome c to the
cytoplasm. Moreover, mitochondrial damage in the course of a
cell’s lifetime may lead to inadvertent leakage of cytochrome c.
In the presence of Bcr-Abl, any small amounts of cytochrome
c released would be rendered impotent, resulting in a failure to
activate caspase 9 and, in turn, caspase 3.
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